Institute for Precision Medicine

Weill Cornell Medicine researchers are working to combat the stark racial disparities in breast cancer outcomes

Findings from a recent study by a team of Weill Cornell Medicine and NewYork-Presbyterian researchers explain why a bladder cancer patient responded exceptionally well to a targeted drug when others did not. 

How a patient and her doctor used precision medicine to fight her deadly uterine cancer.

Weill Cornell Medicine has experienced dynamic growth in its research enterprise over the past five years, an achievement that underscores the institution’s mission to provide patients with the most advanced treatments and therapies.

A new artificial intelligence approach by Weill Cornell Medicine investigators can identify with a great degree of accuracy whether a 5-day-old, in vitro fertilized human embryo has a high potential to progress to a successful pregnancy. 

The deletion of a gene that normally promotes healthy cell division in the prostate encourages the growth of cancer in the gland, according to a new study by Weill Cornell Medicine investigators. The findings, published March 28 in Cancer Cell, suggest that the gene, once deleted, helps to promote tumorous growth.

Dr. Manuel Hidalgo, a leading physician-scientist who specializes in pancreatic cancer and drug development, has been named chief of the Division of Hematology and Medical Oncology in the Weill Department of Medicine at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, effective June 1. 

Being diagnosed with advanced metastatic pancreatic cancer was a grim experience for Steve Price. But thanks to his doctors at Weill Cornell Medicine and NewYork-Presbyterian, state-of-the-art interventional radiology allowed him to receive chemotherapy immediately after biopsy, shrinking his tumors dramatically. 

Dr. Massimo Loda Appointed Chair of the Department of Pathology and Laboratory Medicine at Weill Cornell Medicine and Pathologist-in-Chief at NewYork-Presbyterian/Weill Cornell Medical Center

Gene mutations detected in blood may predict risk of one of the most common forms of adult leukemia a decade before patients are diagnosed with the disease, according to a new study by Weill Cornell Medicine and NewYork-Presbyterian investigators.

The complex life cycle of the parasite that causes malaria has made it a difficult foe to beat. But new insights on how the parasite is transmitted from humans to the mosquitoes that spread malaria may lead to new ways to control this deadly disease.

Dr. Olivier Elemento, a renowned computational biologist and leader in the field of computational genomics and biomedicine, has been named director of the Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell Medicine.

Weill Cornell Medicine has been awarded a five-year, $11.3 million Specialized Programs of Research Excellence grant from the National Cancer Institute to improve the detection, diagnosis and treatment of prostate cancer. 

Growing up in Knoxville, Tennessee, Neel Madhukar always assumed he would become a physician.

To further realize the promise of precision medicine, Igor Tulchinsky, through WorldQuant, LLC, has made a $5 million gift to Weill Cornell Medicine. 

Combining genetic information from a patient’s tumor cells with three-dimensional cell cultures grown from these tumors and rapidly screening approved drugs can identify the best treatment approaches in patients for whom multiple therapies have failed.

A newly discovered genetic mutation that is found in a subtype of prostate cancer is integral to the disease’s development and growth.

Weill Cornell Medicine researchers will receive a grant from the Department of Defense to conduct an in-...

Weill Cornell Medicine (WCM) and the New York Genome Center (NYGC) were...

Study provides a framework for understanding the biological basis for chemotherapy resistance in bladder cancer.